SCCOMEDIUM SIGNALFINANCIAL10-K

SCCO demonstrated strong operational performance with meaningfully higher profitability while dramatically reducing share buyback activity.

The company's robust revenue growth of 24% and substantially higher net income reflect strong operational execution and favorable market conditions. However, the sharp 93% decline in share buybacks suggests management may be prioritizing capital preservation or investment over aggressive shareholder returns, which could signal either capital constraints or strategic shifts toward growth investments.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

SCCO's financials show broad-based strength with revenue growing 24% and operating income expanding 26%, while net income increased substantially. The balance sheet strengthened meaningfully with current assets up 35%, cash growing 32%, and stockholders' equity rising 20%. However, share buybacks declined dramatically from $1.0B to $72M, even as the company increased capital expenditures by 29% to $1.3B, suggesting a strategic pivot toward reinvestment over shareholder distributions.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-92.9%
$1.0B$71.7M

Buyback activity reduced 92.9% — capital being redeployed elsewhere or cash conservation underway.

Accounts Receivable
Balance Sheet
+64%
$1.2B$2.0B

Receivables surged 64% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Net Income
P&L
+50.3%
$1.6B$2.3B

Net income grew 50.3% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
+35.3%
$6.2B$8.4B

Current assets grew 35.3% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+32.1%
$3.3B$4.3B

Cash position surged 32.1% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
+29%
$1.0B$1.3B

Capex increased 29% — ongoing investment in capacity or infrastructure for future growth.

Operating Income
P&L
+26.1%
$5.6B$7.0B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Revenue
P&L
+23.7%
$5.4B$6.7B

Revenue growing 23.7% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
+20.4%
$9.2B$11.0B

Equity base grew 20.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+14.3%
$18.7B$21.4B

Asset base grew 14.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 97 - 98 Item 7.
Management s Discussion and Analysis of Financial Condition and Results of Operations 99 - 125 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 194 - 196 Item 13.
Through December 31, 2025, we have repurchased an aggregate of 119.5 million shares of our common stock for an aggregate cost of $2.9 billion.
These repurchased shares may be used for general corporate purposes.
+7 more — sign up free →
REMOVED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 95 - 96 Item 7.
Management s Discussion and Analysis of Financial Condition and Results of Operations 97 - 123 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 188 - 190 Item 13.
Pursuant to this program, through December 31, 2024 we have purchased 119.5 million shares of our common stock at a cost of $2.9 billion.
We may purchase additional shares from time to time, based on market conditions and other factors.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →